PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29164814-6	2018	Thrombin dependence of ratiometric fluorescence was tested by ex vivo application of RACPPNleTPRSFL and argatroban to cryosections obtained from mouse hind paws on day 1 of serum-transfer arthritis.	argatroban	104-114	coagulation factor II	Mus musculus	0-8	
30254103-5	2018	A pharmacological strategy using the direct thrombin inhibitor argatroban reversed the deleterious effects of PN-1 deficiency.	argatroban	63-73	coagulation factor II	Mus musculus	44-52	
29105740-9	2018	Thrombin generation was shown to occur downstream of PAR1 activation in infected mice via tissue factor exposure as part of the inflammatory response, and thrombin inhibition by argatroban reduced the pathogenicity of the infection with no additive effect to that induced by PAR1 inhibition.	argatroban	178-188	coagulation factor II	Mus musculus	155-163	
33460666-0	2021	Thrombin inhibitor argatroban modulates bone marrow stromal cells behaviors and promotes osteogenesis through canonical Wnt signaling.	argatroban	19-29	coagulation factor II	Mus musculus	0-8	
32238460-7	2020	Interestingly, enhanced thrombin activation in C3-/- TM mice and reduction of kidney injury following attenuation of thrombin generation by argatroban in a serum-transfer nephrotoxic model identified thrombin as a surrogate pathway for complement activation in C3-deficient mice.	argatroban	140-150	coagulation factor II	Mus musculus	117-125	
32238460-7	2020	Interestingly, enhanced thrombin activation in C3-/- TM mice and reduction of kidney injury following attenuation of thrombin generation by argatroban in a serum-transfer nephrotoxic model identified thrombin as a surrogate pathway for complement activation in C3-deficient mice.	argatroban	140-150	coagulation factor II	Mus musculus	117-125	
30102144-2	2018	We previously showed that immediate administration of thrombin inhibitor argatroban post-infection protected mice against hMPV disease.	argatroban	73-83	coagulation factor II	Mus musculus	54-62	
23237573-9	2012	In addition, we treated mice with anti-C5 monoclonal antibodies or with the thrombin inhibitor argatroban.	argatroban	95-105	coagulation factor II	Mus musculus	76-84	
27034473-10	2016	Elevated platelet activation and macrophage accumulation were reversed by treating ApoE(-/-)/Bgn(-/0) mice with the thrombin inhibitor argatroban.	argatroban	135-145	coagulation factor II	Mus musculus	116-124	
26511508-7	2015	Using in silico modeling and drug-target interaction studies, we identified that the U.S. Food and Drug Administration-approved thrombin inhibitor argatroban is a Morf4l1 antagonist.	argatroban	147-157	coagulation factor II	Mus musculus	128-136	
22534729-5	2012	Active thrombin in serum cleaves DPRSFL-ACPP with >90% inhibition by lepirudin or argatroban.	argatroban	85-95	coagulation factor II	Mus musculus	7-15	
22841818-0	2012	Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.	argatroban	60-70	coagulation factor II	Mus musculus	41-49	
22841818-6	2012	Mice were given the direct thrombin inhibitor argatroban ~15 mg/kg/day or its vehicle via a miniosmotic pump for the final 4 weeks of the study.	argatroban	46-56	coagulation factor II	Mus musculus	27-35	
15539922-0	2004	Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.	argatroban	20-30	coagulation factor II	Mus musculus	0-8	
15539922-3	2004	In this study, we evaluated the effect of argatroban, a specific thrombin inhibitor, on the migration and metastasis of B16BL6 melanoma cells.	argatroban	42-52	coagulation factor II	Mus musculus	65-73	
2208129-11	1990	The activity of B16 and its metastatic variants to induce platelet aggregation in the presence of MD805, a synthetic antagonist of thrombin, well correlated with the reactivity of 8F11 to these cells.	argatroban	98-103	coagulation factor II	Mus musculus	131-139	
19966184-3	2010	The 4-wk administration of argatroban, a selective thrombin inhibitor, reduced fasting plasma glucose and ameliorated insulin resistance in these mice.	argatroban	27-37	coagulation factor II	Mus musculus	51-59	
10780325-4	2000	When GR144053, a platelet glycoprotein IIb/IIIa antagonist, or argatroban, a thrombin inhibitor, was applied, the time required to occlusion was prolonged in a dose-dependent manner in all types of mice.	argatroban	63-73	coagulation factor II	Mus musculus	77-85	
2170704-7	1990	Next we examined the effect of Argipidine on thrombin-induced endothelin release from cultured endothelial cells.	argatroban	31-41	coagulation factor II	Mus musculus	45-53